A drug long used to ease the uncomfortable hot flashes linked to menopause may soon find a new place in breast cancer care. Scientists have discovered that certain artificial progesterones, prescribed for decades to relieve menopausal symptoms, can also slow the growth of some breast tumours.

The finding adds a surprising twist to the way doctors may one day support women undergoing hormone-based cancer treatment, potentially improving comfort and cancer control at the same time.

Breast cancer remains the most frequently diagnosed cancer in women worldwide. According to the World Health Organization, it is the most common cancer in women in more than 150 countries, with about 2.3 million new cases recorded each year.

More than 99 per cent of diagnoses occur in women, although a small number of men are also affected. Among these cases, roughly three-quarters are classified as oestrogen receptor positive, often shortened to ER-positive. These tumours grow in response to oestrogen, making hormone manipulation a cornerstone of treatment.

For women with ER-positive breast cancer, therapy usually includes drugs that block or suppress oestrogen. In post-menopausal women, aromatase inhibitors such as letrozole are widely prescribed worldwide.

These medicines reduce the amount of oestrogen produced in the body and have been shown to lower the risk of cancer returning and to improve long-term survival. Their benefits are well established and supported by years of clinical use.

Yet these drugs come at a cost. Many women experience side effects that closely resemble menopausal symptoms. Hot flashes are common and can be severe. Joint and muscle pain often develops, sometimes affecting mobility and sleep. Bone density may decrease, raising the risk of fractures. Cholesterol levels can rise. Taken together, these effects can erode quality of life and make it difficult for patients to remain on treatment, especially when therapy is recommended for five to ten years.

To manage these symptoms, clinicians sometimes turn to synthetic forms of progesterone. One such drug is megestrol acetate, a medication already familiar in oncology and women’s health.

At low doses, it has been shown to reduce the frequency and intensity of hot flashes in people receiving anti-oestrogen therapy. Until recently, its role was largely supportive, aimed at comfort rather than tumour control.

New research now suggests that this supportive therapy may have a more direct effect on cancer itself. In a clinical study led by researchers at a major UK university and published in the journal Nature Cancer, scientists examined whether adding megestrol to standard anti-oestrogen treatment could influence tumour behaviour in ER-positive breast cancer.

The study, known as the PIONEER trial, recruited 244 women with early-stage ER-positive breast cancer from ten hospitals across the United Kingdom. All participants were scheduled for surgery and received drug treatment for a short period beforehand. This design allowed researchers to study changes within the tumour tissue itself.

Participants were randomly assigned to one of three groups. One group received letrozole alone. A second group received letrozole plus a low dose of megestrol, 40 milligrams per day. A third group received letrozole plus a higher dose of megestrol, 160 milligrams per day. The treatment lasted for two weeks before surgery.

Of those who began treatment, 198 completed the course and had tumour samples suitable for detailed laboratory analysis. Researchers focused on markers of cell proliferation, which indicate how quickly cancer cells are dividing and growing. Slowing this process is a key goal of cancer therapy.

The results were striking. Tumours in patients who received megestrol alongside letrozole showed a greater reduction in cell proliferation compared with those treated with letrozole alone. Importantly, this effect was seen in both the low-dose and high-dose megestrol groups. There was no meaningful difference between the two doses in terms of tumour growth suppression.

In practical terms, this means that even a relatively small amount of megestrol may enhance the anti-cancer effect of standard hormone therapy. This finding matters because the side effects of megestrol itself tend to increase with higher doses. These can include weight gain, raised blood pressure, swelling, shortness of breath and, in some cases, an increased risk of blood clots. Using the lowest effective dose could help balance benefits and risks.

The findings sounds promising but still preliminary. The improved control of hot flashes could already help patients stay on anti-oestrogen therapy for longer, indirectly improving outcomes. The new evidence suggests an additional, more direct anti-tumour effect, which could further strengthen the case for combining these treatments.

Scientists involved in the research propose two main mechanisms behind the observed effect. First, by reducing hot flashes and other distressing symptoms, megestrol may improve adherence to long-term endocrine therapy. Patients who feel better are more likely to continue taking their medication as prescribed.

Second, laboratory analyses indicate that megestrol may act directly on tumour cells. It appears to interfere with the way oestrogen receptors bind to DNA within cancer cells, dampening oestrogen-driven signals that promote growth.

The fact that the lower dose performed as well as the higher dose supports the idea that receptor pathways may become saturated at relatively low levels of the drug. Once this saturation point is reached, increasing the dose may add side effects without offering extra benefit.

Despite the encouraging nature of these results, researchers urge caution. The study was relatively small and short. Treatment lasted only two weeks, and the main outcome measure was a biological marker rather than long-term clinical outcomes such as recurrence or survival.

While changes in cell proliferation can provide valuable insight, they do not always predict how a cancer will behave over years.

To change clinical practice, larger and longer trials will be required. Experts suggest that a randomised phase three trial comparing standard anti-oestrogen therapy with and without low-dose megestrol would be an essential next step.

Such a study would need to follow patients for several years and measure outcomes that matter most to patients, including disease-free survival and overall quality of life.

There is also a need for more detailed dose-finding studies. The PIONEER trial tested only two doses and for a brief period. Longer treatment could reveal new safety considerations or confirm that low-dose therapy remains well tolerated over time. Given that many women take endocrine therapy for up to a decade, understanding the long-term effects of adding megestrol is crucial.

Funding remains a challenge. Large trials are expensive and require collaboration across multiple centres. Researchers hope that the wider scientific community and funding bodies will recognise the potential impact of this approach and support further investigation.

If future studies confirm these findings, the implications could be significant. A single, inexpensive medication might ease some of the most troublesome side effects of hormone therapy while also strengthening its anti-cancer effect. This dual action is particularly appealing in a field where adherence to treatment is a persistent problem.

For patients, the prospect of fewer hot flashes and better tumour control is welcome news. For clinicians, it offers a potential tool to personalise care and support women through long treatment journeys. For health systems, it may represent a cost-effective way to improve outcomes using drugs that are already widely available.

Breast cancer care has advanced steadily over recent decades, yet challenges remain, especially in managing long-term therapy. This research highlights how revisiting familiar medicines with fresh questions can yield unexpected benefits.

A treatment once viewed as a simple remedy for menopausal discomfort may, with further study, become an integral part of modern breast cancer management.

For now, experts stress that patients should not change their treatment based on these findings alone. Decisions about hormone therapy and symptom management should always be made in consultation with a medical team.

Still, the study opens a new line of enquiry and offers a hopeful glimpse of how comfort and cancer control might one day go hand in hand.

As researchers continue to explore this promising avenue, women living with ER-positive breast cancer may have reason to look forward to more tolerable and effective treatment options in the years ahead. A good news indeed.